Navigation Links
Advance Nanotech Reports First Quarter 2008 Financial Results

Company achieves four-fold revenue increase as broad corporate changes are


NEW YORK, May 19 /PRNewswire-FirstCall/ -- Advance Nanotech, Inc. (OTC Bulletin Board: AVNA) today reported financial results for its first quarter ended March 31, 2008. This quarter was the first, full fiscal period since the Company refocused its business model from managing the development of a portfolio of early-stage nanotechnologies to developing one technology within the portfolio that has extraordinary immediate and long-term commercial potential: the Owlstone chemical detection system. Highlights from the quarter include:

-- Commenced a realignment of operations to focus on the Owlstone


-- Board approved Bret Bader as incoming CEO effective upon completion of

Owlstone Exchange Agreement

-- Achieved initial product orders and shipments for Lonestar and Owlstone

vapor generators

-- Awarded second patent from the U.S. patent office, bringing total

issued U.S. patents to two, with 17 pending by Owlstone Nanotech, Inc.

Added homeland security expert to its Board of Directors

"The chemical detection industry is a large, rapidly growing market that spans across many commercial sectors, including industrial process control, homeland security, environmental monitoring and healthcare. Owlstone has developed next generation chemical detection products that are based on patented and patent-pending, proprietary technology to port real-time detection capabilities onto a silicon chip. Having successfully concluded the development of the core sensor, we are now developing and shipping product to meet real-time chemical detection needs in a wide range of industries. Given the near completion of the Advance Nanotech restructuring, we are eager to take the reins and rigorously grow our opportunities with our unique chemical detection platform," commente

SOURCE Advance Nanotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
2. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
3. Advanced Life Sciences Announces First Quarter 2008 Financial Results
4. Battelle Collaborating With Korean Partners to Advance Energy Efficiency and Health and Life Sciences Initiatives in Korea
5. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
6. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
7. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
8. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
9. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
10. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
11. Human Genome Sciences Advances Oncology Portfolio
Post Your Comments:
(Date:7/2/2015)... July 2, 2015  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today announced a litigation ... Incorporated v. Verizon Services Corp. et al. , Case ... the Eastern District of Virginia , ... 2015 interpreting certain key claims in favor of the ...
(Date:7/2/2015)... Memphis, TN (PRWEB) , ... July 02, 2015 ... ... in the development and manufacturing of surgical instruments in Orthopedics, announced today the ... orthopedic contract-manufacturing and the world's largest provider of surgical instruments to the Spine ...
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused ... announced that it has completed the dose escalation stage of an ... heart failure.  Nile had previously announced that the study, NIL-CDNP-CT005, was ... Phase II studies. , , ...
... May 7, 2010 HOYA Corporation today,announced financial results for the fourth ... 104.8 billion yen for the quarter,representing an increase of 26.4% from ... recovery in orders in the main business fields,such as Electro-Optics, as well as ... , ...
... the Swedish medical university Karolinska Institutet shows that the ... cholesterol and thereby cause an inflammation that leads to ... receptors, the researchers have managed to inhibit the development ... in the distinguished periodical Journal of Experimental Medicine ...
Cached Biology Technology:Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study 2Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study 3Hoya Announces Fourth Quarter and Full-Year Financial Results 2Hoya Announces Fourth Quarter and Full-Year Financial Results 3New atherosclerosis vaccine gives promising results 2
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/18/2015)... June 18, 2015 This report analyzes the ... the following Product Segments, which includes Immunoassay Analyzers and ... Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay Systems. The ... Canada , Japan , ... , Latin America , and Rest ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... 14, 2011 - Eurofins MWG Operon, an expert in next ... genomic DNA libraries for sequencing with Roche GS FLX or ... shotgun and long paired end (LPE) libraries with different jumping ... 40 kb). After sequencing, the resulting reads are assembled into ...
... the most important genes in the human genome is called ... Roger Leng, a researcher in the Faculty of Medicine & ... inactivated in cancerous cells, allowing tumours to grow. , "Successful ... therapies that could potentially improve the prognosis for cancer patients ...
... on improved methods for determining the amounts of flavanol ... by The Hershey Center for Health and Nutrition, was ... other scientific laboratories. Scientists at Planta Analytica ... a large scale. The Hershey scientists and collaborating ...
Cached Biology News:U of Alberta researcher discovers potential cancer therapy target 2Hershey scientists improve methods for analysis of healthful cocoa compounds 2
... siSolutions siRNA Custom Synthesis Service ... duplex RNA to knockdown any ... (19 RNA base pairs with ... 27-mers, or other lengths of ...
... Rabbit Antibody to CRF ... with the ovine CRF sequence ... Cells and fibres are found ... of rat brain in colchicine ...
Biology Products: